FDA continues to evaluate the overall risks and benefits of abacavir and didanosine.

FDA继续评估阿巴卡伟和地达诺新的总风险和收益。

youdao

FDA continues to evaluate the overall risks and benefits of abacavir and didanosine.

FDA继续评估阿巴卡伟和地达诺新的总风险和收益。

youdao